- Global Pharma News & Resources

Large Prospective Lung Cancer Study To Be Presented at ESMO Congress Shows Idylla™ Reduces EGFR Mutation Testing Turnaround Time by More than a Week, Allowing Faster Patient Management Decisions

Mechelen, Belgium, 14 September 2020 – Biocartis Group NV (the ‘Company’ or ‘Biocartis’), an innovative molecular diagnostics company (Euronext Brussels: BCART), today announces that a large prospective lung cancer study1, co-supported by AstraZeneca, a global science-led biopharmaceutical company (LON: AZN), has been selected to be presented at the renowned European Society for Medical Oncology (‘ESMO’) Virtual Congress taking place between 19-21 September 2020. Rapid and accurate EGFR mutation testing is essential to make informed treatment decisions2 for patients with advanced non-small cell lung cancer (NSCLC), and the study concluded that Idylla™ reduced turnaround time by more than a week versus reference methods, allowing earlier patient management decisions.

The FACILITATE study is a large, prospective, real-world data set study across 16 European sites3 that was launched as part of the agreement between Biocartis and AstraZeneca4, aimed at obtaining faster lung cancer molecular diagnostic biomarker results in Europe. Between January 2019 and July 2020 a large set of 1,370 advanced non-small cell lung cancer (NSCLC) patient samples were tested using the Idylla™ EGFR Mutation Test5 (CE-IVD) and local reference methods6 including targeted next-generation sequencing (NGS). Results showed a 97.6%7 overall percentage agreement between Idylla™ and reference methods. Ninety percent of all samples were tested in less than 7 days using the Idylla™ technology, versus less than 21 days using the reference methods. This demonstrates that Idylla™ improves turnaround time, allowing for fast-track testing when required, complementary to slower existing laboratory processes and systems.

Herman Verrelst, Chief Executive Officer of Biocartis, commented: “A large study with a broad data set such as this one with our partner AstraZeneca, who is at the forefront of lung cancer treatment, shows once again how Idylla™ can make a significant improvement for patients. With Idylla™, a fully automated rapid EGFR mutation diagnostic workflow8 becomes possible, decreasing testing turnaround time and allowing earlier patient management decisions, following diagnosis.”

Prof. Dr. Michael Hummel, Head of the Molecular Pathology Group, Institute of Pathology, Charite - Universitätsmedizin Berlin: “Lung cancer often requires immediate and adequate treatment. Rapid detection of the vast majority of relevant EGFR mutations provides an excellent targeted treatment option avoiding chemotherapy. In our large real-world study it became very obvious that the Idylla™ system is able to support treatment decisions extremely fast and accurate, much faster than the in-house solutions applied.”

The abstract poster will be published during the poster sessions at the ESMO Virtual Congress taking place between 19-21 September 2020 and is available here. Other Idylla™ study abstracts selected for ESMO can bedownloaded from the ESMO website here. .

Editor Details

  • Company:
    • Biocartis Group NV
  • Name:
    • Biocartis Group NV
Last Updated: 15-Sep-2020